Kessler Topaz Meltzer & Check, LLP encourages DexCom investors who have suffered significant losses to contact the firm ...

A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an ...

Dexcom announced the Dexcom G7 15 Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes will ...

The global Blood Glucose Monitoring System Market, valued at US$15.16 billion in 2024, stood at US$16.46 billion in 2025 and is projected to advance at a resilient CAGR of 9.1% from 2025 to 2030, ...

These healthcare stocks have long-term and profitable growth runways.

DexCom (DXCM) just received FDA clearance for Smart Basal, a new device designed to help adults with Type 2 diabetes optimize their insulin dosing using personalized, real-time sensor data. This ...

Dexcom (NSDQ:DXCM) announced today that it plans to launch its G7 15 Day continuous glucose monitor (CGM) in the U.S. next ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

DexCom DXCM recently announced that it has received FDA clearance for its CGM-integrated basal insulin dosing optimizer, ...

Shareholders who purchased shares of DXCM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plai ...

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose ...